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Abstract
Background: Interleukins (IL) play an important role in angiogenesis. Tocopherol possesses immunomodulating
effect in addition to antioxidant property. The objective of this study was to determine whether gamma
tocopherol’s (gT) angiogenic activity in placental network is enhanced via promoting interleukins.
Methods: Pregnant ewes (N = 18) were supplemented, orally, with 500 mg of alpha tocopherol (aT; N = 6) or
1,000 mg of gT (N = 7) or placebo (CON; N = 5) once daily from 107 to 137 days post breeding. Uterine and
placental tissue samples were obtained at the end of supplementation to evaluate relative mRNA expressions of IL-
1b, IL-6, IL-8, Tumor Necrosis Factor (TNF) alpha, Vascular Endothelial Growth Factor (VEGF), kinase insert domain
receptor (KDR; VGFR2; a type III receptor tyrosine kinase), and soluble fms-like tyrosine kniase-1 (sFlt1 or sVEGFR1) in
uterus, caruncle and cotyledon.
Results: Oral supplementation of gT increased IL-6, IL-8, KDR and VEGF mRNA abundances whereas sFlt1 mRNA
abundance was suppressed in uterus, caruncle and cotyledon, compared to aT and placebo treated ewes (P <
0.05). The TNF alpha and IL-1b mRNA abundances were suppressed in uterus, caruncle and cotyledon but TNF
alpha is higher in gT group compared to aT group (P < 0.05), whereas IL-1b was similar between treatment groups
(P > 0.1).
Conclusions: Gamma tocopherol supplementation increased IL-6, IL-8, and KDR mRNA abundances and
suppressed sFlt1 and TNFalpha mRNA abundances thereby increased VEGF mRNA expression and angiogenesis in
placental vascular network during late gestation. It is plausible that the angiogenic effect of gamma tocopherol in
placental vascular network is exerted via an alternate path by enhancing IL-6 and IL-8.
Background
Angiogenesis refers to the formation of new vascular
beds, and is a critical process for normal placental
growth and development [1-3]. Although numerous fac-
tors have been implicated in angiogenesis, recent obser-
vations have led to the identification of the major
factors regulating the angiogenic process, including
those that occur during placental vascularization. These
angiogenic factors include the vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF),
and the angiopoietin (ANG) protein families, as well as
their respective receptors [4-6]. The VEGF is the major
angiogenic growth factor of the placenta because this
protein probably accounts for most of the angiogenic
activity produced by placental tissues [7-11]. The VEGF
acts as specific mitogen for endothelial cells through
specific membrane receptors, kinase domain-containing
receptor (KDR), and the fin-like tyrosine kinase 1(Flt-1)
[12]. When VEGF binds to its receptors, it initiates
auto-phosphorylation, induces tyrosine kinase activity,
and subsequently stimulates cellular responses in normal
and abnormal angiogenesis.
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Several inflammatory interleukins have been linked
with angiogenesis. These interleukins include IL-1, IL-6,
and IL-8 [13-28]. Interleukin (IL)-8 acts as a potent che-
moattractant for neutrophils, the major cellular compo-
nent of acute inflammatory infiltrates [13,14]. In
addition to this proinflammatory function, there is
growing evidence that IL-8 exerts effects on nonimmune
cells, including the vascular endothelium [14]. The
receptors for IL-8 are widely expressed on normal and
various tumor cells and bind IL-8 receptors with high
affinity [15]. IL-8 expression correlates with vascularity
and microvessel counts [16-18]. Similarly IL-6, a multi-
functional cytokine and is a critical factor in various
physiological conditions including immune regulation,
hematopoiesis and inflammation by modulating a variety
of events, such as cell proliferation, differentiation and
apoptosis [19-21]. Studies have demonstrated that
immunostaining for IL-6 was present in both syncytio-
trophoblasts and extra-villous trophoblasts [22]. IL-6 sti-
mulates VEGF synthesis and release, and promotes
angiogenesis occurrence in vivo and in vitro [23-26].
These cytokines could play a role in vascular remodeling
associated with placentation. The cytokine IL-1 mainly
affects inflammatory processes but also possesses var-
ious immune, degradative, and growth promoting prop-
erties. There are two IL-1 agonistic proteins, IL-1a and
IL-1b. Both were shown to contribute to tumor angio-
genesis and invasiveness, but the role of IL-1b is more
evident in these processes [27].
Tocopherol has immunomodulatory effects, besides its
antioxidant properties. Vitamin E is implicated in pla-
cental and embryonic development, whereas its defi-
ciency affects embryo survival, and placental and fetal
development. Alternative effects of Vitamin E have been
recently reported as unrelated to its antioxidant capacity
[28]. It induces the expression of VEGF promoter [28].
Vitamin E (15 mg/day) has been able to decrease abor-
tion rate and to increase IL-6 placental levels, while
both treatments increased placental levels of VEGF [29].
We have shown that oral supplementation of tocopherol
induces angiogenesis in placental vascular network in
late pregnant ewes [10]. The hypothesis of the study is
that the tocopherol’s angiogenic effect following oral
supplementation during late gestation in ewes is via pro-
moting interleukins.
The objective of this study is to investigate whether
tocopherol’s angiogenic activity in placental network is




Eighteen pregnant ewes (2-6 years of age and weighing
approximately 68 kg; bred by different sires), with
similar breeding dates were selected for the current
study. The ewes were maintained under normal pasture
conditions until the beginning of the supplementation
trial. One week prior to the trial, the selected ewes were
moved to the research facility and were penned by treat-
ment groups. The ewes had access to 35 sq ft/ewe pad-
dock lots. In addition they were fed 250 g of
concentrate/ewe/day and free choice hay. This study
was approved by institutional animal care and use com-
mittee at Washington State University (ASAF #03922-
001).
Treatment groups and samples collection
The ewes were randomly assigned to three groups: 1) aT
group (n = 6)–received 500 mg of alpha tocopherol (aT;
Nature’s Bounty, Bohemia, NY 11716), 2) gT group (n =
7)–received 1,000 mg of gamma tocopherol (gT; Kemin
Industries Inc., Des Moines, Iowa 50317), 3) Control
(CON) group (n = 5)–received a placebo. Animals were
supplemented orally, once daily, from approximately 100
to 137 days post breeding (dpb). At the end of the sup-
plementation period (136 ± 1), all ewes were euthanized
and tissue samples were collected from the gravid uterus
and placentomes to evaluate aT and gT concentrations.
Placentomal and uterine tissues were collected close to
the umbilical cord for consistency. Tissue samples were
snap frozen and stored at -70°C until analysis. Caruncle,
cotyledon and intercaruncular uterus samples were also
collected and stored in RNAlater (Qiagen Inc., Valencia,
CA 91355) and frozen at -70°C to evaluate mRNA
expression. Cotyledones were separated from caruncles
by applying strong pressure.
Polymerase chain reaction of selected genes of interest
Total RNA extraction from tissues
Total RNA was extracted from uterine and placentomal
tissues with RNeasy Mini Kit (QIAGEN Inc. Valencia,
CA, USA) according to the manufacturer’s protocol.
RNA concentration was measured using a NanoDrop
spectrophotometer (Thermo Fisher Scientific Inc. West
Palm Beach, FL, USA). Sample absorbance ratio of 260/
280 wave-length was observed to ensure the purity of
RNA and they were close to 2.00. The RNA samples
were stored at -20°C until complementary DNA (cDNA)
preparation.
Polymerase chain reaction of selected genes of interest
The mRNA was reverse-transcribed to cDNA. The
cDNA samples were prepared using the iScript cDNA
Synthesis kit (Bio-Rad, Hercules, CA, USA). A 500 hg
sample of RNA was reverse transcribed in 20 μL reac-
tion at the incubating conditions of 25°C for 5 min, 42°
C for 30 min and 85°C for 5 min; 25 hg/μL RNA
equivalent cDNA was obtained. Qiagen Tag PCR master
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mix (Qiagen, Valencia, CA, USA), a pre-mixed solution
was used to amplify the fragment of the genes of inter-
est. Final concentration of the primers was 0.3 μM.
Initial denaturation was set at 94°C for 3 min. Followed
by 30 cycles of denaturation at 94°C for 1 min, anneal-
ing at 55°C for 1 min and extension at 72°C was pro-
grammed. A final extension step at 72°C for 10 min was
included in thermo-cycling conditions. Primers (Table
1) were designed either using the NCBI website or pri-
mer express version 3.0 (Applied Biosystems Inc., Carls-
bad, CA, USA). Consideration was given to the set of
primers (forward and reverse primers) to ensure separa-
tion of at least an intron and melting temperatures and
CG content were set at optimal, or close to optimal
level. Amplicon was run on a 2% agarose gel and stained
with ethidium bromide for visualization to ensure a sin-
gle amplicon for a set of primers (Additional file 1: Fig-
ure S1).
Determination of mRNA expression using real-time PCR
SYBR green chemistry was applied to observe relative
mRNA expression. Fast SYBR green master mix (2×)
(Applied Biosystems Inc., Carlsbad, CA, USA) was used
to prepare the reaction mix. The final concentration of
each primer was 0.3 μM. A 20 μL aliquot of three tech-
nical replicates were used for each sample. A 1.6 μL
volume of 25 ng/μL RNA equivalent cDNA was present
in the total volume of the three triplicates. StepOne Plus
instrument (Applied Biosystems Inc., Carlsbad, CA,
USA) was used for the real time PCR runs. Pre-cycling
stage was maintained at 95°C for 20 s. Forty cycle
amplification was carried out with the conditions of 95°
C for 3 s and 60°C for 30 s (fast ramp speed conditions
for the fast mixture). A continuous dissociation step was
added to look for additional amplification products.
Carboxy X rhodamine (ROX) dye was set up for the
passive internal reference. The baseline was automati-
cally adjusted to obtain threshold cycles of each sample.
Threshold cycles were normalized to an endogenous
control, b-actin. A standard curve was obtained using 1
in 5 dilutions for each set of primer in order to check
the amplification efficiency. Correlation co-efficient for
the dilution curve was ≥ 0.9900.
Statistical analysis
The RT-PCR data were subjected to ANOVA (SAS Ver-
sion 9.12, Cary, NC, USA) using 2-ΔΔCt values to ascer-
tain statistical significance of any differences in IL-1b,
IL-6, IL-8, TNFa, VEGF, KDR, and sFlt1 expression in
placebo vs. tocopherol-treated groups in the placenta
and uterus [10,30]. There were 3 ewes (2 in CON and 1
in aT groups) with twins. As the outcome remained the
same whether or not the values from the second fetus
of twins were included in the analysis, the results pre-
sented here included values from one fetus of the twins.
It was hypothesized that the mean differences in mRNA
expressions will be 7 fold differences in treated com-
pared to control groups. To detect the same differences
in the mean mRNA expression, with adequate statistical
power (1-b = 0.8) and statistical significance (a = 0.05),
the study will need a sample size of 3 ewes per treat-
ment group.
Table 1 Primers used for cDNA amplification of the targets by RT-PCR
Gene Primer Seq 5’ to 3’ Product length Accession number
IL-1b Forward TCACAGGAAATGAGCCGAGAA 150 NM_001009465
Reverse CAGCTGCAGGGTCGGTGTAT
IL-6 Forward ACACCACCCCAAGCAGACTACT 200 NM_001009392
Reverse CCCAGATTGGAAGCATCCAT
IL-8 Forward GCCAGAAGAAACCTGACAAAAAG 220 NM_001009401
Reverse GCAGTGTGGCCCACTCTCA
VEGF Forward CCTCACCAAAGCCAGCACAT 150 AF071015.1
Reverse CGTCTGCGGATCTTGTACAAAC
KDR Forward GATGCTCGCCTCCCTTTGA 250 AF233076
Reverse GATCCCCATGCCAGCAATC
SFlt1 Forward GCCACGCCTGAAATCTACCA 150 AF233077
Reverse GGCGTTGAGCGGAATGTAGT
TNFa Forward GACCCTCCTCATCCCCTTCT 300 NM_001024860.1
Reverse AGCCCACCCATGTCAAGTTC
b-actin Forward CCAAGGCCAACCGTGAGA 86 NM_001009784.1
Reverse AGCCTGGATGGCCACGT
Ovine Interleukin (IL)-1b, IL-6, IL-8, Vascular Endothelial Growth Factor (VEGF), Kinase insert Domain Receptor (KDR), soluble Fms-Like Tyrosine kniase-1 (sFlt1),
Tumor Necrosis Factor (TNF) a and b-actin cDNA were amplified by RT-PCR from the uterus and placenta total RNA using the above set of primers
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Results
The mRNA expressions of IL-6, IL-8, IL-1b, TNF-a,
VEGF, sFlt1 and KDR in placenta and uterus in toco-
pherol supplemented groups relative to CON (where
CON group is 1), are given in Figures 1, 2 and 3. In
cotyledon (Figure 1) and caruncle (Figure 2), the IL-6,
IL-8, VEGF and KDR in ewes supplemented with gT
were significantly higher in abundance compared to the
CON group (P < 0.05). The IL-1b, sFlt1 mRNA abun-
dances in cotyledon (Figure 1) and sFlt1 mRNA abun-
dance in caruncle (Figure 2) were lower (P < 0.05) in gT
group compared to the CON groups. The supplementa-
tion of aT suppressed mRNA expression of IL-8, IL-1b,
TNF-a and KDR in cotyledon (Figure 1), and IL-1b and
TNF-a in caruncle (Figure 2) compared to placebo trea-
ted ewes (P < 0.05).
In the uterus, the IL-6 and IL-8, VEGF and KDR
mRNA expressions in ewes supplemented with gT were
significantly higher in abundance, where as IL-1b and
sFlt1 was significantly lower in abundance compared to
the CON group (Figure 3). The IL-6, IL-8, IL-1b and
KDR and TNF-a mRNA abundance in ewes supplemen-
ted with aT were significantly lower compared to the
CON group (Figure 3).
Oral supplementation of gT increased IL-6, IL-8, KDR
and VEGF mRNA expression whereas sFlt1 mRNA
expression was suppressed in cotyledon (Figure 1),
caruncle (Figure 2) and uterus (Figure 3) compared to
aT treated ewes (P < 0.05). The mRNA abundances of
both TNF-a and IL-1b was suppressed in uterus, carun-
cle and cotyledon but TNF-a was different between gT
and aT treatment groups whereas IL-1b was similar
between treatment groups (P > 0.1).
Discussion
In this study we observed that supplementation of gT to
pregnant ewes during late gestation increased IL-6, IL-8,
KDR and VEGF mRNA abundances in uterus, caruncle
and cotyledon whereas the mRNA expression of IL-1b,
sFlt1 was suppressed compared to placebo treated ewes.
In contrast, supplementation of aT suppressed mRNA
expression of IL-1b, IL-6 and KDR in both cotyledon
and caruncle, and IL-8 in cotyledon, compared to pla-
cebo treated ewes (P < 0.05).
In our previous study, we showed that the tocopherol
concentrations of uterus and placentome increased fol-
lowing oral supplementation of tocopherol during late
gestation in pregnant ewes [10]. IL-8 signaling has been
shown to promote the transactivation of the epidermal
growth factor receptor in vascular endothelial cells
[31,32], promoting downstream activation of MAPK sig-
naling. In addition, IL-8 signaling has been shown to
induce the phosphorylation of the KDR, (VEGFR-2) in
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Figure 1 Relative mRNA of target genes expressed in cotyledon of late pregnant ewes following oral supplementation of alpha
tocopherol, gamma tocopherol or placebo. a. Interleukin(IL)-6, IL-8, IL-1b, Vascular Endothelial Growth Factor (VEGF), Kinase insert Domain
Receptor (KDR), soluble Fms-Like Tyrosine kniase-1 (sFlt1) and Tumor Necrosis Factor (TNF) a mRNA expressions in cotyledon following gamma
tocopherol (gT) or alpha tocopherol (aT) oral supplementation (× expression relative to control = 1; * P < 0.05).
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Figure 2 Relative mRNA of target genes expressed in caruncle of late pregnant ewes following oral supplementation of alpha
tocopherol, gamma tocopherol or placebo. a. Interleukin(IL)-6, IL-8, IL-1b, Vascular Endothelial Growth Factor (VEGF), Kinase insert Domain
Receptor (KDR), soluble Fms-Like Tyrosine kniase-1 (sFlt1) and Tumor Necrosis Factor (TNF) a mRNA expressions in caruncle following gamma
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Figure 3 Relative mRNA of target genes expressed in uterus of late pregnant ewes following oral supplementation of alpha
tocopherol, gamma tocopherol or placebo. Interleukin(IL)-6, IL-8, IL-1b, Vascular Endothelial Growth Factor (VEGF), Kinase insert Domain
Receptor (KDR), soluble Fms-Like Tyrosine kniase-1 (sFlt1) and Tumor Necrosis Factor (TNF) a mRNA expressions in uterus following gamma or
alpha tocopherol oral supplementation (× expression relative to control = 1; * P < 0.05).
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endothelial barrier [33]. Protein tyrosine kinases are a
further downstream target of IL-8 signaling responses in
endothelial cells [31]. In our previous study, we demon-
strated increased fractal dimension and lowered lacunar-
ity, signs for improved angiogenesis, in placental
vascular network following gT supplementation com-
pared to aT supplemented and control ewes during late
gestation [10]. In this study, we demonstrated increased
IL-8, KDR and VEGF mRNA abundances in gT supple-
mented ewes. The stimulatory effect of IL-8 might plau-
sibly be regulated by increased VEGF mRNA expression,
which is enhanced via both VEGFR1 (low sFlt1 mRNA
abundance) and VEGFR2 (high KDR mRNA
abundance).
Fan et al. (2008) showed that interleukin (IL)-6
increased endothelial progenitor cell proliferation,
migration and in vitro angiogenic-like tubulogenesis
[22]. It appears that lower IL-6 levels may induce a
deregulation leading to an exacerbated inflammation, a
poor angiogenesis and fetal death by ischemia [29].
However, it should be noted that the underlying angio-
genic mechanism is that IL-6 upregulates KDR. IL-6
triggers VEGF-induced angiogenic activity through
increasing VEGF release, up-regulates KDR expression
and phosphorylation through activating ERK1/2 signal-
ing, and stimulates MMP-9 overexpression [34,35]. It is
evident, in this study, that ewes supplemented with gT
had increased IL-6, VEGF and KDR causing enhanced
angiogenesis in the placental vascular network in that
group.
Numerous studies demonstrated a role for IL-6 in
increased blood pressure. For example, plasma levels of
IL-6 are strongly associated with hypertension in
humans and can be reduced by administration of Ang II
receptor antagonists [36-38]. Animal studies showed
that infusion of IL-6 induces hypertension in pregnant
rats [39,40]. Trophoblast cells are capable of responding
to IL-6 [41-43]. Trophoblast cells have a JAK/STAT-sig-
naling pathway that functions downstream of IL-6R acti-
vation. JAK/STAT signaling, downstream of IFN-g
stimulation, is responsible for increased sFlt-1 produc-
tion by human corneal fibroblasts [44]. The authors
speculated that the IL-6 stimulates sFlt-1 and sEng pro-
duction by trophoblast cells in an autocrine manner by
JAK-STAT signaling, and that increased IL-6 contri-
butes to antibody-mediated hypertension in women with
PE via IL-6-induced stimulation of sFlt-1 production by
trophoblasts [44]. Interestingly in this study, sFlt-1
mRNA expression is suppressed in tocopherol treated
groups plausibly explaining that ischemic necrosis is
prevented by such treatment thus favoring angiogenesis.
IL-1b is a potent immunoregulatory and proinflamma-
tory cytokine secreted by a variety of activated immune
cells. Several studies provide evidence that angiogenesis
and VEGF is IL-1 dependent [45-48] and the major
transcriptional activator of the VEGF gene is HIF
(Hypoxia Inducible Factor) [49]. IL-1b induced a pattern
of gene expression to favor vascular permeability invol-
ving the HIF-VEGF axis [50]. Activation of the ERK1/2
pathway by IL-1b may result in the accumulation of
HIF-1a protein, which initiates VEGF secretion in nor-
mal human cytotrophoblast cells. In the previous study,
we observed that VEGF, HIF-1a and HIF-2a mRNA
expressions in caruncle and uterus were greater in ewes
supplemented with gT compared to the ewes in the
CON group which is coincided with improved angiogen-
esis in the placental vascular network in gT group [10].
In the present study, IL-1b mRNA abundance was sup-
pressed in gT treated ewes compared to ewes in the
CON group. It is plausible that the IL-1b mRNA abun-
dance is lower during late gestation. Studies on immu-
nohistochemical localization of IL-1a and IL-1b in
normal human placenta showed that both IL-1a and IL-
1b forms are localized to villous syncytiotrophoblast and
to extravillous trophoblast [51] and there is a gradual
decrease of IL-1 reactivity with increasing gestational
age. Also, IL-1a contributes to angiogenesis in hypoxia,
when IL-1b secretion is reduced to suboptimal levels
[51]. In addition, Molvarec et al., (2011) did not find
association between serum levels of leptin and pro-
inflammatory cytokines in preeclampsia, which might be
explained–at least partly–by the fact that the latter
(especially TNF-a and IL-1b) have a very short-half life
in the maternal circulation [52]. In dogs, the expression
was absent in uterus during diestrus (10-12 days post
ovulation), and preimplantation (10-12 dpb) and placen-
tation sites (day 20-35 dpb) [53].
The aT exerts an inhibitory effect on the release of the
proinflammatory cytokine, IL-1b, via inhibition of the 5-
lipoxygenase pathway [54] and aT supplementation sig-
nificantly lowered levels of C-reactive protein and inter-
leukin-6 [55]. Also, aT inhibits of IL-8 synthesis from
endothelial cells [56]. It is evident that findings from
these studies showed that supplementation of aT sup-
pressed the expression of interleukins. In this study, the
supplementation of aT suppressed mRNA expression of
IL-1b, IL-6 and KDR in placentome, and IL-8 in carun-
cle compared to placebo treated ewes.
It should be noted that the protein expressions work
was not performed in this study. However, protein
expressions of proinflammatory cytokines and angio-
genic markers in sheep placental tissues were reported
in mid and late gestation [57,58].
Conclusions
Gamma tocopherol supplementation increased IL-6, IL-
8 and KDR mRNA expression, and suppressed sFlt1
mRNA expression in uterus, caruncle and cotyledon
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during late gestation. In addition, the VEGF mRNA
expression in uterus, caruncle and cotyledon is also
increased following supplementation during late gesta-
tion. The increase in VEGF mRNA abundance is
enhanced via both VEGFR1 (low sFlt1) and VEGFR2
(high KDR) mRNA abundances. Taken findings from
this study together, it is conceivable that the angiogenic
effect of gamma tocopherol in placental vascular net-
work is exerted via an alternate path by enhancing IL-6
and IL-8 mRNA.
Additional material
Additional file 1: Figure S1. Photograph of the ethidium bromide-
stained electrophoresis gel, with amplicons of the expected sizes.
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